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ABSTRACT 
Controlled clinical trials of pertussis vaccines are reviewed, and 
additional data are presented to elucidate the influence of simul- 
taneous administration of other vaccines on early jsymptoms 
after vaccination and the effect of number of doses, age, and 
dose-interval on observed efficacy. In a randomized placebo- 
controlled trial of a two-component acellular diphtheria, tetanus 
toxoids, pertussis (DTP) vaccine, a five-component acellular 
DTP, an American whole-cell DTP, and a DT vaccins, adverse 
events were documented by questionnaires 24 hours after vac- 
cination in 9823 children 2 to 6 months of age. In another 
ongoing randomized double-blind trial, 82,892 children were 
enrolled in four DTP groups. An interim analysis of relative effi- 
cacy was done when one vaccine was unblinded, due to the 
low efficacy shown in the first trial. In the placebo-controlled trial, 
simultaneous administration of Haemophilus inf/uen.zae type b 
(Hib) vaccine increased the rate of systemic symptoms as com- 
pared to acellular DTP or DT alone. In the ongoing trial, the rel- 
ative risk of culture-confirmed pertussis with cough for 1 or 
more days was 2.82 (2.06-3.88) after two doses of a two- 
component DTP vaccine compared to a three-component, a 
five-component, and a British whole-cell DTP vaccine, com- 
bined. Simultaneous Hib-vaccination is associated with 
increased rates of systemic symptoms compared to DT or 
acellular DTP alone. Two doses of multicomponent acellular 
vaccines and a British whole-cell vaccine seem to confer sig- 
nificant protection against mild and severe pertussis. 
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During the past decade, four placebo-controlled clinical 
trials of pertussis vaccines with similar study design have 
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generated important information on the efficacy and 
safety of two monocomponent, two two-component, two 
three-component, and one five-component acellular per- 
tussis vaccines.1-5 However, there is no agreement on 
how many components should be included in acellular 
vaccines. Basic to this controversy have been the uncer- 
tainties of what should be required from acellular vac- 
cines to permit replacement of whole-cell pertussis 
vaccines and how to interpret safety and efficacy data 
derived from trials that differ in design, number of doses 
given, age at vaccination, vaccination schedule, and simul- 
taneous administration of other vaccines.6‘s This report 
presents new data on adverse events and simultaneous 
vaccination, presents preliminary findings of relative effi- 
cacy estimates of pertussis vaccines after two doses in 
infancy, and discusses efficacy estimates against infection 
and disease of increasing severity obtained in the four 
randomized placebo-controlled trials. 
SUBJECTS AND METHODS 
The influence of simultaneous vaccination with inacti- 
vated polio vaccine, Haemophilus influenzae type B 
(Hib) vaccine, and diphtheria, tetanus toxins, pertussis 
(DTP) vaccines on symptoms within 24 hours of vacci- 
nation was studied when the Hib vaccine was introduced 
in Sweden during the vaccination phase of the Pertussis 
Vaccine Trial I.*s5 In that study, 9829 children born during 
1992, were randomized to receive one of four vaccines: 
a diphtheria and tetanus toxoids and two-component 
acellular pertussis vaccine (two-component acellular DTP 
SmithKline Beecham [SKBI, Rixensart, Belgium) was 
given to 2566 children; a five-component acellular DTP 
vaccine (Connaught Laboratories Limited [CLL] , Toronto, 
Canada) was given to 2587 children; a whole-cell DTP 
vaccine (Connaught Laboratories Incorporated [CLI] 
Swiftwater, PA, licensed in the United States) was given 
to 2102 children; and a Swedish diphtheria and tetanus 
toxoids vaccine (DT) (SBL-vaccin, Stockholm, Sweden) 
was given to 2574 children. The vaccines were given as 
intramuscular injections in the thigh at 2, 4, and 6 months 
of age. Inactivated polio vaccine, SBL-vaccin, or 
lyophilized Hib-vaccine (Pasteur-Merieux, Lyon, France) 
dissolved in the polio vaccine could be administered intra- 
muscularly in the other thigh. Study nurses phoned the 
parents, 1 and 14 days after each trial dose, and asked 
structured questions about common adverse events. Seri- 
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DUS adverse events and contraindicating events were 
reported to the clinical coordinators. Hospital records 
were collected for all study children hospitalized until 2 
months after the last trial dose, or at least until 8 months 
of age. The number of doses given for different combi- 
nations of simultaneously administered vaccines have 
been previously reported.5 In one set of the preplanned 
analyses, the adverse events were stratified for trial vac- 
cines alone, simultaneous administration of polio vac- 
cine, and simultaneous vaccination of Hib vaccine or Hib 
plus polio vaccine at second and third dose (almost all 
children received only the trial vaccines at the first trial 
dose). The number of children receiving trial vaccine and 
Hib vaccine alone at any dose was too small to warrant 
separate strata. The administration of polio and Hib vac- 
cines was not blinded, which may have implications on 
the type and frequency of events reported. 
In the randomized blinded Pertussis Vaccine Trial II, 
relative efficacies of whole-cell and acellular pertussis 
vaccines were studied. This trial included a whole-cell 
DTP (Wellcome, Bechenham, Kent, England) the two- 
component acellular vaccine used in the previous trial,* 
z three-component recombinant pertussis toxoid acellu- 
lar DTP vaccine (Chiron-Biocine, Siena, Italy),’ and a five- 
component acellular DTP vaccine containing higher 
amounts of pertussis toxoid and filamentous hemagglu- 
tinin than in the five-component vaccine used in Trial I.* 
The study was conducted in the whole of Sweden except 
Goteborg and surrounding counties. A total of 100,471 
children were eligible, according to the December 31, 
1994, census of Statistics Sweden. A total of 82,892 
:82.5%) children were enrolled, of whom 82,861 
belonged to the eligible cohort. 
The children were randomized, at the Child Health 
Centers, to receive either of the four blinded vaccines. 
The vaccines were administered intramuscularly at 3, 5, 
and 12 months of age to 88% of the enrolled children. In 
Malmo county, the schedule was 2, 4, and 6 months, to 
bridge with other trials.3z4 
All microbiology laboratories in the country routinely 
reported Bordetella pertussis-positive cultures to the 
Swedish Institute for Infectious Disease Control. These 
reports were matched daily with the file of study chil- 
dren, by means of the identification number assigned to 
each child at birth. In case of a match, a study nurse con- 
tacted the family for clinical follow-up. The date of onset 
of cough and the onset of coughing spasms was docu- 
mented. The course of the illness was followed until the 
end of daily coughing spasms or the end of daily cough- 
ing, whichever came first. 
Study infants with culture-confirmed pertussis were 
classified on the basis of clinical findings. The case defi- 
nition for typical pertussis disease was 21 days or more 
of spasmodic cough combined with laboratory or epi- 
demiologic evidence of pertussis.9 The following case 
definitions were specified in a plan for interim analysis 
of efficacy: notified culture-confirmed B. pertussis with 
one or more days of cough, and 21 days or more of spas- 
modic cough, respectively. Adverse events will be 
reported elsewhere. 
RESULTS 
Safety and Simultaneous Vaccination in Pertussis 
Vaccine Trial I 
Table 1 presents the rates of general symptoms and local 
reactions reported in the telephone interviews after doses 
two and three in children who had received the trial vac- 
cines alone, simultaneously with inactivated polio vac- 
cine, or simultaneously with Hib and polio vaccines. As 
reported previously,* the two- and five-component acel- 
lular DTP vaccines had favorable safety profiles similar 
to the DT vaccine and were much less reactogenic than 
the whole-cell vaccine. The rates of most general symp- 
toms were equally high in the whole-cell DTP vaccine 
group whether or not other vaccines were administered 
simultaneously. In contrast, the rates of general symp- 
toms in the acellular DTP and DT vaccine groups 
increased markedly when other vaccines, particularly Hib 
vaccine, were given simultaneously 
Relative Efficacy, Pertussis Vaccine Trial II 
The low efficacy of the SKB two-component vaccine 
observed in Pertussis Vaccine Trial I made it necessary to 
offer a booster dose to recipients of that vaccine.* Hence, 
that vaccine group was unblinded and the parents were 
contacted. The unblinding made it possible to perform 
an interim analysis of the relative efficacy of the two- 
component vaccine compared with the remaining three 
blinded vaccine groups, the Biocine three-component, 
the CLL five-component, and the Wellcome whole-cell 
vaccines. By July 31, 1996, 468 culture-confirmed cases 
of pertussis had been reported in the trial cohort-278 
of the cases had experienced spasmodic cough for 21 
days or more. 
Tables 2 and 3 show how these cases are distributed 
in the two-component group and in the still-blinded 
groups after one, two, and three trial doses, given at 2, 
4, and 6 months of age (see Table 2) and at 3, 5, and 12 
months of age (see Table 3). The highest monthly inci- 
dence rates were observed after one dose, irrespective of 
the vaccine group or schedule. Thus, the relative risk of 
pertussis in the two-component group compared to the 
blinded group is close to 1 after one trial dose. By the sec- 
ond dose, the two-component vaccine was strikingly less 
protective. The overall relative risk of culture-confirmed 
pertussis with cough of any duration was 2.82 (95% con- 
fidence interval (Cl) 2.06, 3.88) compared to two doses 
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Table 1. Percentage of General Symptoms and Local Reactions within 1 Day after Dose 2 and Dose 3 when Trial Vaccine Was Given 
Alone, Together with Inactivated Polio Vaccine,* or Together with Haemophilus influenzae type b, 61 with or without Polio Vaccine 
DTPa2 SKB DTPa5 CLL DT SBL DTPwc CL/ 
Dose 
No. 
Only +Po/io +Hib & folio On/y +Po/io +Hib & Polio Only +Po/io +Hib & Polio Only +Po/io +Hib & Polio 
2 976 791 781 984 754 825 1016 751 788 702 703 635 
Symptom/Reaction 3 855 952 731 881 936 732 879 955 704 585 844 572 
Temperature 238°C 2 11.8 16.3 25.4 12.9 17.6 27.7 13.6 17.3 24.9 73.0 74.1 75.6 
3 17.8 20.4 26.6 18.2 23.8 27.6 15.0 20.5 28.9 60.5 68.7 65.6 
Antipyretics 2 5.0 6.1 24.2 5.6 4.9 28.4 4.4 5.5 25.8 69.6 59.1 78.7 
3 7.1 5.9 22.5 6.8 5.7 22.1 7.0 4.8 21.3 62.6 52.6 69.3 
Fretful 2 31.9 33.9 53.6 29.7 37.0 53.8 32.1 34.8 54.7 84.3 85.3 86.6 
3 30.4 30.8 47.1 30.3 31.7 44.2 31.3 33.2 46.7 72.2 74.4 72.6 
Unusual cy 2 2.9 4.5 16.3 3.0 4.0 14.4 2.5 2.8 15.2 26.1 22.4 30.2 
3 1.5 1.5 6.8 1.6 2.0 5.7 2.4 1.6 5.4 11.2 8.0 11.7 
Crying 21 hr 2 0.8 1.9 6.8 0.7 2.0 4.9 1.4 1.5 5.6 7.6 10.4 9.8 
3 1.5 1.5 6.8 1.6 2.0 5.7 2.4 1.6 5.4 11.2 8.0 11.7 
Anorexia 2 7.7 9.2 13.3 6.9 9.5 11.1 5.7 7.6 11.2 25.7 26.4 24.9 
3 5.5 8.5 9.7 7.0 8.2 9.6 6.4 8.5 7.9 15.9 17.9 18.4 
Vomit 2 4.2 5.2 5.6 5.1 5.0 5.4 5.2 5.6 6.5 8.2 6.7 7.4 
3 4.8 5.0 5.7 4.5 4.4 4.0 5.0 5.2 5.2 5.1 5.5 5.8 
Tender 2 6.7 9.7 14.8 6.3 8.7 16.2 6.9 8.0 17.2 59.4 63.1 58.2 
3 6.2 8.5 12.4 8.3 11.9 11.6 6.4 8.5 13.9 52.6 50.8 47.7 
Nodule 2 1.5 1.8 1.3 1.2 2.3 1.2 2.5 1.8 1.7 9.4 10.8 9.8 
3 4.8 5.7 3.8 8.6 6.4 4.5 4.0 4.1 3.7 11.9 8.9 10.7 
*SmithKline Beecham two-component acellular DTP; +Pasteur-Merieux. 
of the still-blinded vaccines. Comparisons of protection 
for the follow-up period of 25 to 26 months from the 
second dose at 5 months of age in the 3, 5, 12 months 
schedule, and the third dose at 6 months of age in the 
2, 4, 6 months schedule were considered relevant to 
assess the risks and benefits of delaying the third dose 
until 12 months of age. The average incidence per 1000 
person-months of culture-confirmed pertussis with cough 
of any duration for the two-component vaccine was 0.246 
after 6 months of age in the 2,4,6 months schedule and 
0.345 after 5 months of age in the 3, 5, 12 months sched- 
ule. The corresponding rates for the blinded groups were 
0.128 in the 2, 4, 6 months schedule and 0.093 in the 3, 
5, 12 months schedule. These observations suggest that 
during the available follow-up period, the 2, 4,16 months 
schedule conferred somewhat better protectio’n for the 
two-component vaccine, whereas the 3, 5, 12 months 
schedule conferred better protection for the more eff- 
cacious still-blinded vaccines. 
DISCUSSION 
Simultaueous Vaccinations and Safety 
The high rates of systemic symptoms in the whole-cell 
DTP group given alone or simultaneously with other vac- 
cines are in accordance with previous studies.‘OJ1 There 
are differences in the reported rates of fever, prolonged 
crying, and use of antipyretics among recipients of acel- 
lular vaccine.‘-* The lowest rates have been reported in 
trials without a whole-cell vaccine arm.2 The present 
results indicate that simultaneous administration of Hib 
vaccine increases the rates of common systemic symp- 
toms as compared to when acellular DTP or DT are 
administered alone. Thus, comparisons of the reacto- 
genicity of acellular pertussis vaccines may be con- 
founded by simultaneous administration of other more 
reactogenic vaccines. By stratifying and thereby control- 
ling for such confounders, the safety of the acellular 
Table 2. Case Distribution of Culture-Confirmed Pertussis in Groups Vaccinated at 2, 4, and 6 Months of Age* 
2 Id Cough 2 27d Spasmodic Cough 
DTPaZ Blinded DTPa2 Blinded 
Number of Doses n Inc, n Inc, n lnc, n km 
1 2 0.32689 9 0.48022 1 1 .I6349 6 0.32014 
(N = 2551) (N = 7643) (N = 2551) (N = 7643) 
2 6 1.01371 3 0.16274 4 0.67581 1 0.054247 
(N = 2523) (N = 7542) (N = 2523) (N = 7542) 
3 16 0.26005 24 0.13055 8 0.13003 12 0.065273 
(N = 2510) (N = 7479) (N = 2510) (N = 7479) 
*Includes cas?s reported before July 31, 1996; n = number of cases; lncm = incidence per 1000 person-months; N = number of vaccinees. 
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Table 3. Case Distribution of Culture-Confirmed Pertussis in Groups Vaccinated at 3, 5, and 12 Months of Age* 
t Id Cough P 2 Id Spasmodic Cough 
DTPa2 Blinded DTPa2 Blinded 
Number of Doses n /ncm n lncm n lncm n lncm 
1 35 0.70909 88 0.57597 26 0.52675 67 0.43852 
(N = 18,145) (N = 54,553) (N = 18,145) (N = 54,553) 
2 74 0.57209 71 0.18278 58 0.44840 39 0.10040 
(N = 17,929) (N = 53,769) (N = 17,929) (N = 53,769) 
3 80 0.23613 60 0.058945 30 0.088548 26 0.025543 
(N = 17,663) (N = 32,598) (N = 17,663) (N = 52,958) 
* Includes cases reported before July 31, 1996; n = number of cases; Inc, = incidence per 1000 person-months: N = number of vaccinees. 
vaccines used in Pertussis Vaccine Trial I were further 
substantiated. 
The rates of fever of 38°C or higher in recipients of 
Hib vaccine concomitant with inactivated polio vaccine 
and either acellular DTP or DT were higher in this study 
than previously reported for Hib vaccine alone.” The dif- 
ference may be due to differences in trial design or meth- 
ods of data collection, or may indicate that simultaneous 
vaccination with Hib and other vaccines is associated 
with an increased rate of low grade fever. 
What Efficacy Should Be Required of Acellular 
Pertussis Vaccines? 
What should pertussis vaccines protect against, and what 
reduction in disease incidence is to be required from the 
vaccines? In the study protocol of the first efficacy trial 
of acellular pertussis vaccines in Sweden, it was stated, 
Following the recommendations of the WHO Advi- 
sory Group on Clinical Trials (1984), the initial sam- 
ple size was calculated to be large enough to detect 
as statistically significant a vaccine efficacy of 70% or 
greater under the assumption that any less efficacious 
vaccine is unlikely to be adopted for routine use and 
is of no interest. . .it was judged preferable to conduct 
the trial not only to determine if the candidate vac- 
cines were at least 70% effective, but to estimate the 
vaccine efficacy as precisely as possible.. I* 
Expressed assumptions for the sample size calcula- 
tions were consequently “. . .B Vaccine efficacy (VE) is 
90% . . .C . we want the lower limit of the confidence 
interval for efficacy to be >70%.” In that trial, vaccine effi- 
cacy against laboratory-confirmed or epi-linked pertussis 
after two doses of a two-component vaccine (Biken Insti- 
tute, Osaka, Japan) at 6 to 12 months of age was 58% 
(95% CI 35, 77) for any cough, and 78% (95% CI 58, 89) 
for more than 30 days of cough. The corresponding esti- 
mates for a Biken one-component vaccine was 41% (95% 
CI 12, 60) and 77% (95% CI 58, SS).” Based on these 
analyses and later folIow-up,13 it is concluded that the 
two-component vaccine provided better protection 
against pertussis than the monocomponent vaccine. 
These vaccines were not licensed in Sweden because of 
questionable efficacy and safety. Subsequently, when the 
plan of the National Institute of Infectious Diseases and 
Allergy sponsored trial Sweden I was being developed, 
the following aims were stated in the study protocol: “(i) 
to estimate the protection of pertussis vaccines against 
typical pertussis as compared to placebo; (ii) to estimate 
the relative protection against atypical or subclinical infec- 
tion.” According to the study protocol, the rationale for 
the second aim was: “Inclusion of additional antigens 
(besides iPT & FHA) may further enhance protection 
against infection. This issue may be crucial for the selec- 
tion of components included in future acellular pertus- 
sis vaccines.“s 
To address both these questions, a two-component 
vaccine and a five-component vaccine were selected for 
the Sweden I triaI,*ss based on an American multicenter 
safety and immunogenicity study of 13 candidate vac- 
cines.13 Additional information on two three-component 
vaccines was obtained in a concomitant trial in Italy3 The 
same batch of whole-cell DTP vaccine from CLI was used 
in the Italian and Swedish trials. In Figure 1, available vac- 
cine efficacy estimates are shown for varying duration of 
cough as presented in the preplanned analyses from the 
cited trials.‘-* The estimates for the Biken one- and two- 
component vaccines are based on two doses administered 
between 5 and 12 months of age; the one-component 
vaccine manufactured by AMVAX Inc. (Beltsville, MD) was 
given in three doses at 3, 5, and 12 months of age.2 Both 
monocomponent vaccines showed Iittle protection against 
infection and mild disease but better protection against 
pertussis with prolonged cough. The Biken two-compo- 
nent vaccine had higher observed efficacy than the SKB 
two-component vaccine given at 2, 4, and 6 months of 
age. This may be due to improved efficacy if at least one 
dose is given at an older age when any maternal anti- 
bodies have disappeared and the immune response may 
have matured, or may be explained by differences in vac- 
cine characteristics. The interim analysis of Pertussis Vac- 
cine Trial II, presented here, supports that higher 
estimates of efficacy are to be expected after three doses 
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Figure 1. Vaccine efficacy estimates for laboratory-confirmed per- 
tussis with cough for 1 day or more, 7 or more days, 14 or more days, 
21 or more days, and 30 or more days, according to randomized dou- 
ble-blind placebo-controlled trials. The Biken one- and iwo-compo- 
nent vaccines were tested in two doses at 5 to 12 months of age’,‘*; 
the AMVAX vaccine in three doses at 3, 5, and 12 months of age*; 
the CLI whole-cell DTP was tested in two trials, in Italy and in 
Sweden, in three doses at 2, 4, and 6 months of age.3,4 The SKB 
three-component DTP and the Biocine three-component DTP 
were tested in the Italian Trial.3 The SKB two-component DTP and 
the CLL five-component DTP also were tested in Sweden4 
in a 3, 5, 12 months schedule than after three doses in a 
2, 4, 6 months schedule. Thus the lower estimates 
observed for the SKB two-component vaccine than for 
the Biken one- and two-component vaccines and the 
AMVAX one-component vaccine may be explained by dif- 
ferences in vaccination schedules rather than by inherent 
differences in the vaccines. 
Figure 1 shows that the multicomponent vaccines 
confer better protection against mild disease and also 
better protection against more severe disease.-in spite 
of the fact that the vaccination schedule was 2, 4, and 6 
months without a booster. Also when differences in case 
ascertainment and diagnostic methods are taken into 
account, data from these four controlled trials indicate 
that multicomponent pertussis vaccines are more effica- 
cious against both severe and mild pertussis than vac- 
cines containing one or two components. The interim 
analysis of the relative efficacy of the SKB two-component 
vaccine compared to the remaining three blinded vac- 
cine groups in the Pertussis Vaccine Trial II also indicates 
that a recombinant three-component vaccine, a. five-com- 
ponent vaccine, and a British whole-cell vaccine confer 
considerable protection already after two doses admin- 
istered before 6 months of age. Thus, two doses in 
infancy, followed by a third dose around 1 year of age 
may be recommended for highly efficacious acellular per- 
tussis vaccines. This is supported by nonsignificant find- 
ings in a separate interim analysis of the trial, performed 
by the Data Safety Monitoring Board, to address the ques- 
tion of whether any of the still-blinded vaccines showed 
inferior protection that warranted termination of that 
trial arm (Norrby. Personal communication). Thus, a two- 
plus-one dose schedule during infancy is recommended 
for highly efficacious acellular pertussis vaccines. Such 
vaccines may be efficient tools not only to control but to 
eradicate pertussis, and would provide the opportunity 
in many countries to reduce the number of doses of DTP 
given in infancy and preschool years from four to three 
doses. Such a reduction may require amendments to the 
current global program for vaccines and immunization,‘* 
but may be a basis for improved and cost-effective vac- 
cination programs worldwide. 
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